Evaluation of Outcomes of Dupilumab Therapy in Patients with Atopic Dermatitis – A Single-Center Retrospective Longitudinal Study Authors: Andrea Miniello, Francesco Pugliese, Ilaria Pepe, Giovanna Pastore, Maria Lassandro, Chiara Calabrese, Eustachio Nettis Published: 2026 ABSTRACT Background:Eczema control is a measurable construct currently recommended to be monitored for the management of atopic dermatitis (AD) in clinical trials.Aims:Measuring eczema-related outcomes with a focus on patient-perceived eczema control in AD patients over a period of 12 months during which they were treated with dupilumab.Methods:All patients with severe AD (Eczema Area and Severity Index (EASI) score ≥24) who initiated dupilumab from June 2020 to February 2022 and continued treatment for at least one year were included in this study. Monitored outcomes include EASI, Atopic Dermatitis Control Tool (ADCT), Dermatology Life Quality Index (DLQI) and peak pruritus/sleep Numerical Rating Scale (NRS).Results:Sixty-one patients were included. At 4 months of treatment, absolute cutoff score EASI ≤7 was reached by 59% of patients, ADCT ≤7 by 50.8%, DLQI ≤5 by 78.7%, itch-NRS ≤4 by 68.8% and sleep NRS ≤4 by 8.5%. At 12 months of treatment, absolute cutoff score EASI ≤7 was reached by 85.2%, ADCT ≤7 by 83.6%, DLQI ≤5 by 86.9%, itch-NRS ≤4 by 88.5% and sleep NRS ≤4 by 91.8%. Minimally clinically important difference of ≥5 ADCT points and ≥4 DLQI points were achieved, respectively, by 96.7% and 88.5% of patients at 4 months and by 100% and 96.7% at 12 months.Conclusions:This study found that treatment with dupilumab consistently achieved disease control at 12 months of therapy. At 4 months, statistically meaningful improvements relative to baseline were observed for all the patient-related outcomes even though only half of our cohort reached the treat-to-target cutoffs for EASI and ADCT. Introduction Atopic dermatitis (AD, also known as eczema) is a common inflammatory skin condition characterized by eczematous lesions, intense itching and a chronic or relapsing clinical course, which leads to a substantial physical, psychological, social and economic burden on patients, their caregivers and their families.[1234]. It is the most common paediatric skin condition, affecting up to 18.6% of European children,[5] while the prevalence of AD among adults ranges from 2.1% to 4.9% across European countries.[6] The management of this disease focuses on regular skin health care with the use of emollient ointments and avoidance of trigger factors, while also providing anti-inflammatory therapy according to the symptoms severity: mild cases can be treated with topical therapy, while moderate-severe disease requires phototherapy or systemic immunomodulatory agents.[7] In the case in which these therapies are ineffective or contraindicated, oral JAK inhibitors[8] or biologic drugs can be employed.[9] At the time of the study, the only biologic drug approved for the treatment of moderate-severe AD in children and adults was dupilumab, a fully human G4 subclass monoclonal antibody which blocks the shared receptor for IL-4 and IL-13 (IL-4R subunit alpha, IL-4Rα) and thus inhibits the signalling pathways of these cytokines, which are pivotal in driving type 2 inflammation in multiple diseases; in this way, dupilumab provides rapid clinical benefits (most patients report improvement within 2 weeks) while also presenting an excellent safety profile.[1011] Different patient-reported outcome measures (PROMs) and physician-reported outcome measures have been devised to assess the disease activity and control and the patient’s quality of life during therapy.[12] The efficacy of dupilumab has been reported in many studies;[131415161718192021222324] however, in many of them, AD is evaluated using exclusively physician-reported outcomes, thus limiting the patient input on the treatment outcomes. Regarding those studies which included patient-reported outcomes, a 2022 systematic review showed that the most commonly PRO used in English to assess quality of life was the Dermatology Life Quality Index (DLQI) questionnaire, while the most commonly PRO used in English to assess disease severity was the Peak Pruritus Numerical Rating Scale (itch-NRS), and Peak Sleep NRS.[12] In 2019, the Harmonizing Outcome Measures for Eczema (HOME) initiative held their VII consensus meeting and recommended the use of the Atopic Dermatitis Control Tool (ADCT),[2526] or in alternative Recap of atopic eczema (RECAP),[27] as a core outcome measure of long-term disease control to be included in all clinical trials of atopic dermatitis among other scores.[2829] Still, to this day, there are very few published studies which include all these instruments.[30313233] In this study, we assess the control of AD in patients treated with dupilumab through the use of both physician- and patient-reported outcomes, including ADCT, trying to assess the improvement in the patients’ physical and psychological experience while comparing it with the objective improvement in the clinical signs. Methods Study design and population This was a single-center retrospective longitudinal cohort survey study in which we investigated the patient’s experience over a period of 12 months during which they were treated with dupilumab. In our department (Allergy and Clinical Immunology Unit, Policlinico of Bari, Italy), we started using the ADCT questionnaire as a routine follow-up tool in June 2020 thus we decided to include in our study all AD patients who initiated dupilumab in June 2020 to February 2022 and continued the therapy for at least one year without interruptions while managing to attend routine follow-up visits at 16 weeks and 52 weeks from the beginning of the treatment. Patients with any missing PROM data due to missed follow-up visits or due to incomplete and/or incorrect filling of the questionnaires and patients who interrupted the therapy before 12 months were excluded. All these patients obtained dupilumab through public health reimbursement, which in Italy is available for the treatment of severe atopic dermatitis in adult patients with EASI score ≥24 (despite topical therapy) for whom treatment with cyclosporine is contraindicated, ineffective or not tolerated, or in children and adolescents (aged 6 to 17) with EASI score ≥24 or one of the following characteristics: (a) involvement of face or sensitive body areas; (b) itch-NRS ≥7; (c) CDLQI ≥10. Each patient received an initial dose of 600 mg of dupilumab injected subcutaneously, followed by 300 mg every 14 days. Dupilumab was administered either as monotherapy or concomitantly with topical corticosteroids. All the patients were naïve to biological therapy. Outcomes and data management Demographic data and medical history of comorbidities and atopic diseases (asthma, allergic rhinoconjunctivis, food allergy, chronic spontaneous urticaria, nasal polyposis) were collected at baseline. Blood samples were collected in the month before the start of the treatment to measure total serum immunoglobulin E (IgE) and eosinophil count. Patients were evaluated three times: at the beginning of the treatment and at 16 and 52 weeks after initiation of dupilumab. At each visit, the disease severity was assessed by physicians from our department using the Eczema Area and Severity Index (EASI).[34] During the visit, patients reported their experience by compiling the Italian version of multiple questionnaires to provide different validated PROMs: - Itch/sleep NRS are single-item scales which are used to assess itch severity[35] and sleep disturbance[36] using a 0-to-10 score (0 meaning best score and 10 meaning worst score).- Dermatology Life Quality Index (DLQI) is a 10-item questionnaire which uses a 0-to-30 score to evaluate health-related quality of life (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment). A change of ≥4 points in the DLQI total score is considered clinically meaningful.[3738]- ADCT is a 6-item tool which evaluates severity of AD symptoms, number of days experiencing intense itch, and the degree of bother caused by AD and how much it affects sleep, daily activities, and mood and emotions, and it is the first PRO tool which can assess itch, sleep and impact of AD on daily activities in a single questionnaire. The total score ranges from 0 to 24 (higher scores indicating poorer control), and a change of ≥5 points is the threshold for meaningful within-person change. A total score <7 indicates adequate disease control, with a sensitivity/specificity of 0.87/0.86; alternatively, two other methods based on the evaluation of the individual items can be used to identify patients “not in control” with higher sensitivity (0.96) and good sensibility (0.68): 1) a six-item pattern with at least “Moderate/Moderately” on items 1, 3, 5, or 6, or “3–4 days” on item 2, or at least “1 or 2 nights” on item 4 (sleep), or 2) a 4-item pattern with at least “Moderate/Moderately” on items 1 and 3, or “3–4 days” on item 2, or at least “1 or 2 nights” on item 4 (sleep). - Itch/sleep NRS are single-item scales which are used to assess itch severity[35] and sleep disturbance[36] using a 0-to-10 score (0 meaning best score and 10 meaning worst score). - Itch/sleep NRS are single-item scales which are used to assess itch severity[35] and sleep disturbance[36] using a 0-to-10 score (0 meaning best score and 10 meaning worst score). - Dermatology Life Quality Index (DLQI) is a 10-item questionnaire which uses a 0-to-30 score to evaluate health-related quality of life (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment). A change of ≥4 points in the DLQI total score is considered clinically meaningful.[3738] - Dermatology Life Quality Index (DLQI) is a 10-item questionnaire which uses a 0-to-30 score to evaluate health-related quality of life (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment). A change of ≥4 points in the DLQI total score is considered clinically meaningful.[3738] - ADCT is a 6-item tool which evaluates severity of AD symptoms, number of days experiencing intense itch, and the degree of bother caused by AD and how much it affects sleep, daily activities, and mood and emotions, and it is the first PRO tool which can assess itch, sleep and impact of AD on daily activities in a single questionnaire. The total score ranges from 0 to 24 (higher scores indicating poorer control), and a change of ≥5 points is the threshold for meaningful within-person change. A total score <7 indicates adequate disease control, with a sensitivity/specificity of 0.87/0.86; alternatively, two other methods based on the evaluation of the individual items can be used to identify patients “not in control” with higher sensitivity (0.96) and good sensibility (0.68): 1) a six-item pattern with at least “Moderate/Moderately” on items 1, 3, 5, or 6, or “3–4 days” on item 2, or at least “1 or 2 nights” on item 4 (sleep), or 2) a 4-item pattern with at least “Moderate/Moderately” on items 1 and 3, or “3–4 days” on item 2, or at least “1 or 2 nights” on item 4 (sleep). - ADCT is a 6-item tool which evaluates severity of AD symptoms, number of days experiencing intense itch, and the degree of bother caused by AD and how much it affects sleep, daily activities, and mood and emotions, and it is the first PRO tool which can assess itch, sleep and impact of AD on daily activities in a single questionnaire. The total score ranges from 0 to 24 (higher scores indicating poorer control), and a change of ≥5 points is the threshold for meaningful within-person change. A total score <7 indicates adequate disease control, with a sensitivity/specificity of 0.87/0.86; alternatively, two other methods based on the evaluation of the individual items can be used to identify patients “not in control” with higher sensitivity (0.96) and good sensibility (0.68): 1) a six-item pattern with at least “Moderate/Moderately” on items 1, 3, 5, or 6, or “3–4 days” on item 2, or at least “1 or 2 nights” on item 4 (sleep), or 2) a 4-item pattern with at least “Moderate/Moderately” on items 1 and 3, or “3–4 days” on item 2, or at least “1 or 2 nights” on item 4 (sleep). It is one of the most recently developed tools of assessment of AD, and it showed convergent validity with DLQI and skin pain NRS.[2526] As therapeutic targets, we set an absolute cutoff score of EASI ≤7, itch-NRS ≤4, sleep NRS ≤4 and DLQI ≤5, according to the 2021 international consensus on the treat-to-target strategy for the management of atopic dermatitis.[39] Statistical analysis IBM SPSS Statistics for Windows (version 26) was used for statistical analysis, with a two-sided significance level of 0.05. Generalized Estimating Equation (GEE) models were used to estimate parameters for each outcome, including ADCT, DLQI, NRS itch and sleep and EASI from baseline, week 16 and week 52. As long as the missing values are completely random, parameter estimation in GEE remains robust. Due to the percentage of missing data in this study being so low, we used the intention-to-treat (ITT) principle when fitting our data to the models. GEE models have been implemented to estimate the effects of dupilumab treatment on target clinical outcomes over time. The results for continuous outcomes were presented as mean score changes with 95% CIs and P values. For the dichotomies, the regression coefficients were converted into odds ratios (OR). Results Sample characteristics Our database included a total of 101 patients suffering from AD who were treated with dupilumab during the observed period. Thirty-five patients had missing data and were thus excluded, while five patients deliberately discontinued therapy within the first year: two due to unsatisfactory clinical response and three due to patient-related reasons. It was possible to recover complete data from 61 patients who managed to attend all the follow-up visits and ended up being included in the study. 67.2% of these patients included in the study (n = 41) were male, with a median age of 26 (IQR = 20) ranging from 14 to 72 years of age. All the patients were Caucasians (100%). Most of them (75.4%) had a history of atopy [more details in Table 1]. Thirteen patients (21.3%) reported dupilumab-related side effects (all cases of conjunctivitis), which did not lead to suspension of therapy. PROMs and EASI values before the beginning of dupilumab therapy are reported in Table 2. At baseline, no patient had adequately controlled disease according to ADCT total score (ADCT <7). Table 1Characteristics of population at baselinen=61Male, n (%)41 (67.2%)Age at beginning of questionnaire Mean (SD)31.7 (14.5) Median (IQR)26 (20)Caucasian patients, n (%)61 (100%)Patients w/atopic diseases, n (%)46 (75.4%) Rhinoconjunctivitis42 (68.8%) Asthma18 (29.5%) Nasal polyposis3 (4.9%) Food allergy15 (24.6%)Cases of dupixent-related side-effects, n (%)13 (21.3%)Baseline eosinophil count (10^3/mL) Mean (SD)0.466 (0.417) Median (IQR)0.335 (0.421) Missing data, n (%)17 (26.6%)IgE count (kU/L) Mean (SD)3516.2 (4628.3) Median (IQR)2000 (4287) Missing data, n (%)17 (26.6%) Characteristics of population at baseline Table 2Mean changes and Odds of outcome effectiveness at the three time pointsContinuous outcomesBaselineMonth 4Month 12Month 12 – BaselineMonth 4 – BaselineMonth 12 – Month 4 B (95% CI) P B (95% CI) P B (95% CI) P ADCT (mean (SD*)19.67 (SD.43)7.33 (SD 0.72)3.08 (SD 0.50)−16.59 (−17.70 to−15.48)<0.001−12.34 (−13.70 to−10.97)<0.001−4.25 (−5.08 to−3.41)<0.001DLQI (mean (SD)14.51 (SD 0.94)3.49 (SD 0.59)2.25 (SD 0.51)−12.26 (−14.18 to−10.35)<0.001−11.02 (−12.86 to−9.17)<0.001−1.25 (−2.11 to−0.38)0.005NSR pruritus (mean (SD)8.57 (SD 0.18)3.00 (SD 0.34)0.87 (SD 0.30)−6.70 (−7.38 to−6.03)<0.001−5.57 (−6.26 to−4.88)<0.001−1.13 (−1.67 to 0.59)<0.001NRS sleep (mean (SD)6.39 (SD 0.37)1.56 (SD 0.29)1.08 (0.24)−5.31 (−6.09 to−4.52)<0.001−4.84 (−5.59 to−4.08)<0.001−4.75 (−0.94 to−0.01)<0.001EASI (mean (SD)30.64 (SD 1.03)6.74 (SD 0.68)3.51 (SD 0.48)−27.13 (−29.12 to−25.15)<0.001−23.90 (−25.81 to−21.99)<0.001−3.23 (−4.26 to−2.20)<0.001 Dichotomous outcomes Baseline Month 4 Month 12 OR† P OR P OR P ADCT<7, n (%)030 (49.2)51 (83.6)––––5.27<0.001DLQI ≤5, n (%)9 (14.8)48 (78.7)53 (86.9)21.33<0.00138.27<0.0011.790.055NSR pruritus ≤4, n (%)043 (70.5)54 (88.5)––––3.230.004NRS sleep ≤4, n (%)16 (26.2)54 (88.5)56 (91.8)21.70<0.00131.50<0.0011.450.316EASI ≤7, n (%)036 (59.0)52 (85.0)––––4.01<0.001*SD was calculated as the standard error of the mean (SEM) multiplied by√n, †OR was calculated as exp (β). ADCT=Atopic Dermatitis Control Tool, DLQI=Dermatology Life Quality Index, EASI=Eczema Area and Severity Index, NRS=Numeric Rating Scale Mean changes and Odds of outcome effectiveness at the three time points *SD was calculated as the standard error of the mean (SEM) multiplied by√n, †OR was calculated as exp (β). ADCT=Atopic Dermatitis Control Tool, DLQI=Dermatology Life Quality Index, EASI=Eczema Area and Severity Index, NRS=Numeric Rating Scale EASI and PROMs during the first year of treatment Median baseline EASI was 26 (IQR = 20). Only two patients started dupilumab with an EASI score <24 because they underwent therapy with cyclosporin A in the months before starting biologic therapy, and despite the efficacy, they suspended it due to side effects. At 4 months after treatment with dupilumab, median ADCT and EASI values were 7 (IQR = 4.7) and 5 (IQR = 5.1), respectively. All the PROMs and EASI differed significantly from baseline at this point (P < 0.001). The minimally clinically important difference (MCID) compared to baseline for ADCT (≥5 points) and DLQI (≥4 points) was achieved in 59 (96.7%) and 54 (88.5%) patients, respectively. At 12 months after treatment with dupilumab, median ADCT was 1.5 (IQR = 5). The MCID for ADCT and DLQI compared to the 4-month follow-up visit was achieved in 31 (50.8%) and 13 (21.3%) patients, respectively. Further statistically significant improvement in ADCT, itch-NRS, sleep NRS and EASI was observed compared to month 4 (P < 0.001) [Table 2, Figure 1]. Mean ADCT, DLQI, EASI and NRS score (±1SD as error bars) at baseline, 4 and 12 months follow-up For most patients, it was not possible to recover results for the individual ADCT items and only the total score was available; thus, we decided to assess clinical control with the standard method as reported on the ADCT official site (i.e. total ADCT <7). According to this method, 31 patients (50.8%) were considered “in control” at 4 months, and 51 (83.6%) patients were considered “in control” at 12 months [Table 3, Figure 2]. Table 3Methods of assessment of clinical control and improvement according to ADCT and DLQITreat-to-target cutoffsBaseline4 months12 monthsEASI ≤7, n (%)0 (0%)36 (59%)52 (85.2%)ADCT <7, n (%)0 (0%)31 (50.8%)51 (83.6%)DLQI ≤5, n (%)9 (14.7%)48 (78.7%)53 (86.9%)Itch-NRS ≤4, n (%)0 (0%)42 (68.8%)54 (88.5%)Sleep NRS ≤4, n (%)16 (26.2%)54 (88.5%)56 (91.8%) Clinical improvement Baseline vs. 4 months Baseline vs. 12 months ΔADCT ≥5*, n (%)59 (96.7%)61 (100%)ΔDLQI ≥4†, n (%)54 (88.5%)59 (96.7%)*Patients with a decrease in ADCT score equal or superior to 5 compared to the score calculated at baseline, †Patients with a decrease in DLQI score equal or superior to 4 compared to the score calculated at baseline. ADCT=Atopic Dermatitis Control Tool, DLQI=Dermatology Life Quality Index, EASI=Eczema Area and Severity Index, NRS=Numeric Rating Scale Methods of assessment of clinical control and improvement according to ADCT and DLQI *Patients with a decrease in ADCT score equal or superior to 5 compared to the score calculated at baseline, †Patients with a decrease in DLQI score equal or superior to 4 compared to the score calculated at baseline. ADCT=Atopic Dermatitis Control Tool, DLQI=Dermatology Life Quality Index, EASI=Eczema Area and Severity Index, NRS=Numeric Rating Scale Disease control according to different treat-to-target cutoffs at baseline, 4 and 12 months follow-up At 4 months of treatment, absolute cutoff score EASI ≤7 was reached by 59% of patients, ADCT ≤7 by 50.8%, DLQI ≤5 by 78.7%, itch-NRS ≤4 by 68.8% and sleep NRS ≤4 by 8.5%. At 12 months of treatment, absolute cutoff score EASI ≤7 was reached by 85.2% of patients, ADCT ≤7 by 83.6%, DLQI ≤5 by 86.9%, itch-NRS ≤4 by 88.5% and sleep NRS ≤4 by 91.8%. Discussion By blocking both the IL-4 signalling via type I receptor (composed of the IL-4Rα and common gamma chain) and the IL-4/13 signalling via type II receptor (composed of the IL-4Rα and IL-13R subunit alpha 1) and the subsequent type 2 response which involves the release of proinflammatory cytokines, chemokines and IgE, dupilumab has been demonstrated to reduce the severity of atopic dermatitis and its associated symptoms while improving the quality of life and psychological well-being of the patients.[40] In this study, approximately half of the patients achieved clinical control at month 4 of therapy with dupilumab, according to ADCT, and the percentage increased to 83.6% at month 12. A questionnaire study by Oosterhaven et al.[30] showed that this percentage tends to be considerably lower using the alternative ADCT single-items methods of disease control (66.3% vs. 38.5% and 40.4%); unfortunately, our study did not permit to evaluate of eczema control in these ways due to missing data regarding the individual items. Even though the vast majority of patients experienced a significant improvement in terms of ADCT and DLQI at both T4 and T12 [Table 3], the percentage of patients considered “in control” at 4 months in our study was lower compared to the ones observed at 2 or 3 months in the RELIEVE-AD study[3141] and at 4 months in a recent study conducted by Barei et al.,[32] but at 12 months the results become comparable. Furthermore, these studies reveal that the percentage of patients considered clinically controlled (ADCT <7) after the first year of treatment remains stable for up to 3 years and 4 years, respectively. Both studies also noticed that the results observed after the first year for the other PROMs taken into consideration were similar or progressively better to the ones taken at 12 months. Interestingly, Barei et al. also conducted a correlation analysis between ADCT and the other scores, suggesting that ADCT could represent a potential versatile tool which could replace the daily use of other PROs for the overall assessment of treatment outcomes due to its consistent correlation in time with other scores. Finally, a study conducted on 28 Japanese patients aged 80 years and above) showed a similar trend to our study in achieving clinical control at 4 months.[33] A limitation of this retrospective observational study is the fact that some patients who experienced unsatisfactory clinical responses decided to interrupt the treatment before the completion of the first year and could not be monitored, thus creating a positive bias. Still, most patients achieved improvement and most of those who did not experience complete control of the symptoms kept undergoing dupilumab treatment due to lack of alternative biological therapeutical options until 2022; in fact, tralokinumab (anti-IL-13 monoclonal antibody) became reimbursable by the Italian National Health Service in July 2022,[42] while abrocitinib and upadacitinib (JAK-1 inhibitors) became reimbursable in January 2023.[4344] Conflicts of interest There are no conflicts of interest.